Global Hepatitis Delta Virus (HDV) Infection Market Growth (Status and Outlook) 2024-2030

Global Hepatitis Delta Virus (HDV) Infection Market Growth (Status and Outlook) 2024-2030

Hepatitis D, also known as delta hepatitis, is a liver infection caused by the Hepatitis D virus (HDV). It is considered a satellite virus, as it requires the presence of the Hepatitis B virus (HBV) to replicate and cause infection. HDV infects individuals either as a co-infection with HBV or as a superinfection in those already infected with HBV. Hepatitis D is caused by the HDV, which can only infect individuals already infected with HBV. HDV can spread through contact with infected blood or body fluids, similar to HBV transmission routes. Injection drug use, exposure to infected blood, or unprotected sexual contact with an HBV/HDV-infected person are common risk factors for acquiring Hepatitis D.

The global Hepatitis Delta Virus (HDV) Infection market size is projected to grow from US$ 1585 million in 2024 to US$ 8063 million in 2030; it is expected to grow at a CAGR of 31.1% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Hepatitis Delta Virus (HDV) Infection Industry Forecast” looks at past sales and reviews total world Hepatitis Delta Virus (HDV) Infection sales in 2022, providing a comprehensive analysis by region and market sector of projected Hepatitis Delta Virus (HDV) Infection sales for 2023 through 2029. With Hepatitis Delta Virus (HDV) Infection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hepatitis Delta Virus (HDV) Infection industry.

This Insight Report provides a comprehensive analysis of the global Hepatitis Delta Virus (HDV) Infection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Hepatitis Delta Virus (HDV) Infection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hepatitis Delta Virus (HDV) Infection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hepatitis Delta Virus (HDV) Infection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hepatitis Delta Virus (HDV) Infection.

The increasing global prevalence of HDV infection is a significant market driver that is boosting the Market CAGR. HDV infection, which occurs along with hepatitis B virus (HBV) infection, is considered the most severe form of viral hepatitis, resulting in increased morbidity and fatality rates. The World Health Organization (WHO) estimates that over 15-20 million people globally are chronically infected with HDV. This growing incidence of HDV infection highlights the critical need for improved diagnoses, therapies, and preventive measures, which will drive market expansion.

This report presents a comprehensive overview, market shares, and growth opportunities of Hepatitis Delta Virus (HDV) Infection market by product type, application, key players and key regions and countries.

Segmentation by Type:
Acute Hepatitis D
Chronic Hepatitis D

Segmentation by Application:
Clinic
Hospital
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Acute Hepatitis D
Chronic Hepatitis D

Segmentation by Application:
Clinic
Hospital
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BIOSIDUS
Hoffmann-La Roche Ltd.
Zydus Cadila
NanoGen Healthcare Pvt. Ltd.
AMEGA Biotech
Rhein-Minapharm
PROBIOMED SA de CV
3SBio Group
Eiger BioPharmaceuticals
Arrowhead Pharmaceuticals, Inc
MYR Pharmaceuticals
Hepatera
Janssen Biopharmaceuticals
Antios Therapeutics, Inc.
PharmaEssentia Corporation
Replicor, Janssen Pharmaceuticals, Inc
Apotex Corp.
Mylan N.V
Aurobindo Pharma Limited
Gilead Sciences, Inc.
GlaxoSmithKline

Please note: The report will take approximately 2 business days to prepare and deliver.